Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 3:52 AM
Ignite Modification Date: 2025-12-25 @ 3:52 AM
NCT ID: NCT03376802
Eligibility Criteria: Inclusion criteria: * Overweight to obese male and female subjects. * Body mass index 28 - 40 kg/m2. * 18 to 50 years of age * Fasting plasma glucose ≤125 mg/dL. * Glycated hemoglobine (HbA1c) ≤6.5%. * Obesity associated mild concomitant diseases allowed (eg, mild hypertension, mild hypercholesteremia, and hyperlipidemia). * No concomitant medication allowed except stable treatment with statins or antihypertensive drugs (except ß-blocker). * Females should be either postmenopausal, or, if perimenopausal should have a normal regular menstrual cycle and should start or continue stable treatment with a monophasic oral contraceptive. Exclusion criteria: * Elevated liver enzymes, lipase, amylase, or calcitonin at screening. * Current participation in an organized diet / weight reduction program or clinical trial of weight control or weight loss attempt, plans for major changes in physical activities or significant change in body weight in the 2 months prior to screening. * Any condition possibly affecting gastric emptying or absorption from gastro-intestinal tract (eg, gastric surgery, gastrectomy, bariatric surgery, malabsorption syndromes, gastroparesis, abdominal surgery other than appendectomy or hysterectomy. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 50 Years
Study: NCT03376802
Study Brief:
Protocol Section: NCT03376802